Clinical Trial Update: Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate [Phase 2]

View source ↗

Summary

Phase 2 trial examining neoadjuvant abiraterone plus androgen deprivation therapy for intraductal carcinoma of the prostate.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ADT (androgen deprivation therapy)
• Abiraterone (abiraterone)

Snippet

Sponsor: West China Hospital | Conditions: Prostate Cancer | Phase 2 | Status: UNKNOWN